HC Advisors’s Akebia Therapeutics AKBA Stock Holding History

HC Advisors’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-10,000	Closed	-$3K	–	86
2022 Q3	$3K	Buy	+10,000	New	+$3.92K	﹤0.01%	85
2021 Q1	–	Sell	-14,000	Closed	-$39K	–	90
2020 Q4	$39K	Sell	14,000 -2,389	-15%	-$6.97K	0.03%	87
2020 Q3	$41K	Buy	+16,389	New	+$144K	0.03%	75

Other funds holding AKBA

AIM

Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

OCM

Ovata Capital Management Hong Kong $715M AUM 19.57% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

HC Advisors's AKBA Position: Q4 2022 in Review

HC Advisors sold out of Akebia Therapeutics (AKBA) in Q4 2022, closing a stake of 10,000 shares — an estimated $3K sold.

HC Advisors first reported a position in AKBA in Q3 2020 and held it in 3 quarters. The position peaked at $41K in Q3 2020. 75 funds tracked by Wall St. Rank hold AKBA as of Q4 2022.

HC Advisors reported no remaining Akebia Therapeutics position as of Q4 2022 after selling out during the quarter.
HC Advisors sold 10,000 Akebia Therapeutics shares in Q4 2022, an estimated $3K.
HC Advisors first reported a position in Akebia Therapeutics in Q3 2020 and held it in 3 quarters.
HC Advisors's Akebia Therapeutics position peaked at $41K in Q3 2020.
75 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2022.

Based on HC Advisors's 13F filing for Q4 2022, filed 9 Feb 2023.